Stock Comparison

JNJ vs SRPT

Johnson & Johnson vs Sarepta Therapeutics Inc

The Verdict

SRPT takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

SRPT

Sarepta Therapeutics Inc

6.8

out of 10

Solid Pick

Head-to-Head

$557.1B

Market Cap

$1.9B

26.5

P/E Ratio

29.0

21.8%

Profit Margin

3.0%

26.3%

Return on Equity

4.9%

0.6

Debt-to-Equity

0.7

Conservative

Overall Risk

Moderate

1.0

DVR Score

6.8

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

SRPT6.8/10

Score Change Explanation: The previous analysis (2026-04-05) highlighted "persistent commercial execution issues for Elevidys, reflected in Q4 2025's wider-than-expected loss and reduced 2026 revenue guidance." The Q1 2026 earnings, reported on May 6, 2026, represent a material positive change. Sarepta reported a significant swing to GAAP operating income of $358.4 million and GAAP net income of $...

Full SRPT Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.